Definitive Contract HHSF223201610121C
Award Date 9/13/16
Potential Completion Date 9/29/18
Potential Value $220K
Federal Agency
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Cost No Fee
Place of Performance
Storrs, CT 06269, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
8
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This is a $1,530,889.00 definitive contract awarded by the Food and Drug Administration (FDA) to the University of Connecticut (UConn) to conduct a research study titled "Investigating the Impact of API Purity, Excipient Source and Manufacturing Process on Performance and Quality of Complex siRNA Lipid Nanoparticles". The contract has a performance period ending on September 21, 2027 and is a cost-type contract with no fee. UConn, a non-profit 1862 land-grant university, has...
- This is a $973,150.35 definitive, firm fixed price contract awarded by the Food and Drug Administration (FDA) to the University of Connecticut (UConn) for a study on the "Impact of Polymer Attributes on the Performance of In Situ Forming Implants." The contract has a completion date of September 9, 2023 and was awarded on March 6, 2020. UConn, a non-profit educational institution, will leverage its expertise in scientific research and specialized services to support this FDA study....
- The University of Connecticut has been awarded a definitive contract by the Department of Health and Human Services Food and Drug Administration to continue processing liposomal nanoparticles as reference materials for drug product development. With a potential value of $349,364, this time and materials contract does not have a set-aside designation and is to be completed by May 31, 2023. As the prime contractor, the University will utilize its expertise in nanotechnology and materials...
- This is a $1,417,987.00 federal contract awarded by the Food and Drug Administration (FDA) to the University of Connecticut (UConn). The contract is a Definitive Contract without a set-aside designation. The contract involves a comparative trial of different packaging components of an opioid packaging solution to evaluate their impact on opioid safety outcomes. UConn is working with Hartford Hospital and the UConn Health Center as subcontractors on this research project, which aims to identify...
- The Food and Drug Administration awarded a $1,103,886 definitive contract to the University of Connecticut for research on the impact of API CQAS on in situ forming implants and understanding in vitro and in vivo performance differences on September 22, 2023, under full and open competition. Place of performance is Storrs, CT. The originating solicitation was a Broad Agency Announcement posted November 14, 2022, seeking advanced research and development proposals to further regulatory science...
- The University of Connecticut (UConn) was awarded a $1,310,263 cost-no-fee definitive contract by the Food and Drug Administration (FDA) to enhance and validate in vitro-in vivo correlation (IVIVC) methods for long-acting injectable drug products to accelerate their generic development. The contract is part of the FDA's Broad Agency Announcement for Advanced Regulatory Science, which solicits research and development proposals across various areas to modernize regulatory science and support...
- The Food and Drug Administration awarded a definitive contract to University of Connecticut for assessing long-acting injectable formulations using in vivo imaging on September 29, 2020, with a ceiling value of $1.13 million and ultimate completion date of September 29, 2024. The contract carries cost-no-fee pricing and no set-aside designation. Place of performance is Silver Spring, MD. Work is now deobligated and closed out. Service Contract Inventory reporting shows the contract invoiced $784...
- This is a $500,000 firm-fixed-price definitive contract awarded by the Food and Drug Administration (FDA) to the University of Florida (UF) Division of Sponsored Research for a pharmacokinetic comparison study of locally acting orally inhaled drug products. The contract does not have a set-aside designation, indicating UF competed for and was awarded the contract based on its extensive research capabilities. UF is a major research institution that provides a wide range of goods and services to...
- This is a definitive contract awarded by the Defense Health Agency to the University of Connecticut (UConn) on September 21, 2015. The contract has a ceiling value of $2,248,917.00 and an ultimate completion date of September 22, 2020. It is not set aside under any special designation. The contract involves UConn conducting research and development work focused on miniaturizing sensor signal processing units, optimizing potentiostats, and testing new sensor iterations in vivo. UConn has...
- This is a $3,526,785.00 definitive, firm fixed-price contract awarded by the Food and Drug Administration (FDA) to the Regents of the University of Michigan, doing business as the University of Michigan, for Prediction of In Vivo Performance Analysis Services. The contract has no set-aside designation. The University of Michigan is providing a range of research and development services under this contract, including developing high-performance computational models to simulate small intestine...